Eylea vs Vuity
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Eylea | US Vuity | |
|---|---|---|
| Generic name | aflibercept | pilocarpine ophthalmic |
| Drug class | VEGF Inhibitor (Eye Injection) | Cholinergic Muscarinic Agonist (Eye Drop) |
| Treats | Wet macular degeneration, diabetic eye disease | Age-related blurry near vision (presbyopia) |
| Category | Eye Health | Eye Health |
| Manufacturer | Regeneron | AbbVie (Allergan) |
| Year approved | 2011 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $90M | $70M |
| Common side effects | Eye floaters, Eye pain, Increased eye pressure, Bleeding in the eye | Headache, Eye redness, Trouble with night vision, Eye pain |
Frequently asked questions
Is Eylea or Vuity better?
Neither is universally "better." Eylea (aflibercept) and Vuity (pilocarpine ophthalmic) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Eylea and Vuity?
Eylea is a VEGF Inhibitor (Eye Injection) made by Regeneron, while Vuity is a Cholinergic Muscarinic Agonist (Eye Drop) made by AbbVie (Allergan). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Eylea has the larger estimated TV advertising budget of the two.